<DOC>
	<DOCNO>NCT00596583</DOCNO>
	<brief_summary>The primary objective study test hypothesis DYME safe effective drug facilitate continuous curvilinear capsulorhexis ( CCC ) selectively stain anterior capsule . Secondary objective compare safety effectiveness DYME small dose API .</brief_summary>
	<brief_title>DY001 : Safety Effectiveness DYME Agent Selective Staining Anterior Capsule During Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Have cataract sufficiently opaque/mature/brunescent , surgeon 's assessment , dye could facilitate surgery ; Be age least 18 year old time enrollment ; Be able tolerate surgical procedure 3 hour ; Be medical condition suitable cataract surgery ; Able willing participate study examination visit schedule ; Understand freely consent participate study . In either eye , ocular infection inflammation within past 3 month ; Known allergy BBG 250 ; Uncontrolled intercurrent disease include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia ; Active treatment cancer systemic infection within past month ; Active treatment systemic corticosteroid within past month ; Previous participation Study contralateral eye ; Participation another clinical trial involve investigational therapeutic past 30 day 5.5 halflives ( applicable ) , whichever longer ; Unwillingness participate study inability give inform consent ; Any medical condition opinion Investigator may compromise research subject 's safety ability participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>